Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Identifieur interne : 000D68 ( PubMed/Checkpoint ); précédent : 000D67; suivant : 000D69Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Auteurs : Carlos Solano [Espagne] ; Monica Slavin [Australie] ; Alissa J. Shaul [États-Unis] ; David I. Marks [Royaume-Uni] ; Catherine Cordonnier [France] ; Oliver A. Cornely [Allemagne] ; Antonio Pagliuca [Royaume-Uni] ; Lael Cragin [États-Unis] ; Isidro Jarque [Espagne] ; Carolina Garcia-Vidal [Espagne] ; Sonja Sorensen [États-Unis] ; David J. Vanness [États-Unis] ; Claudie Charbonneau [France] ; Jon Andoni Barrueta [Espagne] ; Carmen Peral [Espagne] ; Marina De Salas-Cansado [Espagne] ; Eric J. Bow [Canada]Source :
- Mycoses [ 1439-0507 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Analyse coût-bénéfice, Antifongiques (usage thérapeutique), Antifongiques (économie), Espagne, Fluconazole (usage thérapeutique), Fluconazole (économie), Humains, Infections fongiques invasives (), Infections fongiques invasives (ethnologie), Infections fongiques invasives (microbiologie), Infections fongiques invasives (économie), Itraconazole (usage thérapeutique), Itraconazole (économie), Techniques d'aide à la décision, Transplantation de cellules souches hématopoïétiques, Triazoles (usage thérapeutique), Triazoles (économie), Voriconazole (usage thérapeutique).
- MESH :
- ethnologie : Infections fongiques invasives.
- microbiologie : Infections fongiques invasives.
- usage thérapeutique : Antifongiques, Fluconazole, Itraconazole, Triazoles, Voriconazole.
- économie : Antifongiques, Fluconazole, Infections fongiques invasives, Itraconazole, Triazoles.
- Adulte, Analyse coût-bénéfice, Espagne, Humains, Infections fongiques invasives, Techniques d'aide à la décision, Transplantation de cellules souches hématopoïétiques.
English descriptors
- KwdEn :
- Adult, Antifungal Agents (economics), Antifungal Agents (therapeutic use), Cost-Benefit Analysis, Decision Support Techniques, Fluconazole (economics), Fluconazole (therapeutic use), Hematopoietic Stem Cell Transplantation, Humans, Invasive Fungal Infections (economics), Invasive Fungal Infections (ethnology), Invasive Fungal Infections (microbiology), Invasive Fungal Infections (prevention & control), Itraconazole (economics), Itraconazole (therapeutic use), Spain, Triazoles (economics), Triazoles (therapeutic use), Voriconazole (therapeutic use).
- MESH :
- chemical , economics : Antifungal Agents, Fluconazole, Itraconazole, Triazoles.
- chemical , therapeutic use : Antifungal Agents, Fluconazole, Itraconazole, Triazoles, Voriconazole.
- economics : Invasive Fungal Infections.
- ethnology : Invasive Fungal Infections.
- microbiology : Invasive Fungal Infections.
- prevention & control : Invasive Fungal Infections.
- Adult, Cost-Benefit Analysis, Decision Support Techniques, Hematopoietic Stem Cell Transplantation, Humans, Spain.
Abstract
Patients undergoing allogeneic haematopoietic stem cell transplantation (alloHSCT) are at risk of developing invasive fungal infections (IFIs). Even with introduction of oral triazole antifungal agents (fluconazole, itraconazole, posaconazole and voriconazole) IFI-associated morbidity and mortality rates and economic burden remain high. Despite their proven efficacy, it is currently unknown which is the most cost-effective antifungal prophylaxis (AFP) agent. To determine the costs and outcomes associated with AFP, a decision-analytic model was used to simulate treatment in a hypothetical cohort of 1000 patients undergoing alloHSCT from the perspective of the Spanish National Health System. Generic itraconazole was the least costly AFP (€162) relative to fluconazole (€500), posaconazole oral suspension (€8628) or voriconazole (€6850). Compared with posaconazole, voriconazole was associated with the lowest number of breakthrough IFIs (36 vs 60); thus, the model predicted fewer deaths from breakthrough IFI for voriconazole (24) than posaconazole (33), and the lowest predicted costs associated with other licensed antifungal treatment and IFI treatment in a cohort of 1000. Voriconazole resulted in cost savings of €4707 per patient compared with posaconazole. Itraconazole demonstrated a high probability of being cost-effective. As primary AFP in alloHSCT patients 180 days posttransplant, voriconazole was more likely to be cost-effective than posaconazole regarding cost per additional IFI and additional death avoided.
DOI: 10.1111/myc.12552
PubMed: 27562016
Affiliations:
- Allemagne, Australie, Canada, Espagne, France, Royaume-Uni, États-Unis
- Angleterre, Catalogne, Communauté de Madrid, Grand Londres, Manitoba, Maryland, Wisconsin, Île-de-France
- Barcelone, Créteil, Londres, Madrid, Paris, Winnipeg
- Université du Manitoba
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:27562016Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.</title><author><name sortKey="Solano, Carlos" sort="Solano, Carlos" uniqKey="Solano C" first="Carlos" last="Solano">Carlos Solano</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Clínico, INCLIVA-University of Valencia, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clínico, INCLIVA-University of Valencia, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Slavin, Monica" sort="Slavin, Monica" uniqKey="Slavin M" first="Monica" last="Slavin">Monica Slavin</name><affiliation wicri:level="1"><nlm:affiliation>Royal Melbourne Hospital, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Royal Melbourne Hospital, Melbourne, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Shaul, Alissa J" sort="Shaul, Alissa J" uniqKey="Shaul A" first="Alissa J" last="Shaul">Alissa J. Shaul</name><affiliation wicri:level="2"><nlm:affiliation>Evidera, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Evidera, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Marks, David I" sort="Marks, David I" uniqKey="Marks D" first="David I" last="Marks">David I. Marks</name><affiliation wicri:level="1"><nlm:affiliation>University Hospitals Bristol NHS Foundation Trust, Bristol, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Hospitals Bristol NHS Foundation Trust, Bristol</wicri:regionArea><wicri:noRegion>Bristol</wicri:noRegion></affiliation></author><author><name sortKey="Cordonnier, Catherine" sort="Cordonnier, Catherine" uniqKey="Cordonnier C" first="Catherine" last="Cordonnier">Catherine Cordonnier</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Henri Mondor, Assistance Publique-Hopitaux de Paris and UPEC, Creteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Henri Mondor, Assistance Publique-Hopitaux de Paris and UPEC, Creteil</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author><author><name sortKey="Cornely, Oliver A" sort="Cornely, Oliver A" uniqKey="Cornely O" first="Oliver A" last="Cornely">Oliver A. Cornely</name><affiliation wicri:level="1"><nlm:affiliation>Department I of Internal Medicine, Clinical Trials Centre Cologne, Centre for Integrated Oncology Köln Bonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, German Centre for Infection Research, University of Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department I of Internal Medicine, Clinical Trials Centre Cologne, Centre for Integrated Oncology Köln Bonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, German Centre for Infection Research, University of Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Pagliuca, Antonio" sort="Pagliuca, Antonio" uniqKey="Pagliuca A" first="Antonio" last="Pagliuca">Antonio Pagliuca</name><affiliation wicri:level="3"><nlm:affiliation>King's College Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>King's College Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Cragin, Lael" sort="Cragin, Lael" uniqKey="Cragin L" first="Lael" last="Cragin">Lael Cragin</name><affiliation wicri:level="2"><nlm:affiliation>Evidera, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Evidera, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Jarque, Isidro" sort="Jarque, Isidro" uniqKey="Jarque I" first="Isidro" last="Jarque">Isidro Jarque</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitari i Politècnic La Fe, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitari i Politècnic La Fe, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Garcia Vidal, Carolina" sort="Garcia Vidal, Carolina" uniqKey="Garcia Vidal C" first="Carolina" last="Garcia-Vidal">Carolina Garcia-Vidal</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Sorensen, Sonja" sort="Sorensen, Sonja" uniqKey="Sorensen S" first="Sonja" last="Sorensen">Sonja Sorensen</name><affiliation wicri:level="2"><nlm:affiliation>Evidera, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Evidera, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Vanness, David J" sort="Vanness, David J" uniqKey="Vanness D" first="David J" last="Vanness">David J. Vanness</name><affiliation wicri:level="2"><nlm:affiliation>University of Wisconsin and Visiting Scientist at Evidera, Madison, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Wisconsin and Visiting Scientist at Evidera, Madison, WI</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Charbonneau, Claudie" sort="Charbonneau, Claudie" uniqKey="Charbonneau C" first="Claudie" last="Charbonneau">Claudie Charbonneau</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer Inc, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer Inc, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Barrueta, Jon Andoni" sort="Barrueta, Jon Andoni" uniqKey="Barrueta J" first="Jon Andoni" last="Barrueta">Jon Andoni Barrueta</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer Inc, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pfizer Inc, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Peral, Carmen" sort="Peral, Carmen" uniqKey="Peral C" first="Carmen" last="Peral">Carmen Peral</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer Inc, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pfizer Inc, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="De Salas Cansado, Marina" sort="De Salas Cansado, Marina" uniqKey="De Salas Cansado M" first="Marina" last="De Salas-Cansado">Marina De Salas-Cansado</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer Inc, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pfizer Inc, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Bow, Eric J" sort="Bow, Eric J" uniqKey="Bow E" first="Eric J" last="Bow">Eric J. Bow</name><affiliation wicri:level="4"><nlm:affiliation>CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>CancerCare Manitoba, University of Manitoba, Winnipeg, MB</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27562016</idno><idno type="pmid">27562016</idno><idno type="doi">10.1111/myc.12552</idno><idno type="wicri:Area/PubMed/Corpus">001178</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001178</idno><idno type="wicri:Area/PubMed/Curation">001175</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001175</idno><idno type="wicri:Area/PubMed/Checkpoint">001175</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001175</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.</title><author><name sortKey="Solano, Carlos" sort="Solano, Carlos" uniqKey="Solano C" first="Carlos" last="Solano">Carlos Solano</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Clínico, INCLIVA-University of Valencia, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clínico, INCLIVA-University of Valencia, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Slavin, Monica" sort="Slavin, Monica" uniqKey="Slavin M" first="Monica" last="Slavin">Monica Slavin</name><affiliation wicri:level="1"><nlm:affiliation>Royal Melbourne Hospital, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Royal Melbourne Hospital, Melbourne, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Shaul, Alissa J" sort="Shaul, Alissa J" uniqKey="Shaul A" first="Alissa J" last="Shaul">Alissa J. Shaul</name><affiliation wicri:level="2"><nlm:affiliation>Evidera, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Evidera, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Marks, David I" sort="Marks, David I" uniqKey="Marks D" first="David I" last="Marks">David I. Marks</name><affiliation wicri:level="1"><nlm:affiliation>University Hospitals Bristol NHS Foundation Trust, Bristol, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Hospitals Bristol NHS Foundation Trust, Bristol</wicri:regionArea><wicri:noRegion>Bristol</wicri:noRegion></affiliation></author><author><name sortKey="Cordonnier, Catherine" sort="Cordonnier, Catherine" uniqKey="Cordonnier C" first="Catherine" last="Cordonnier">Catherine Cordonnier</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Henri Mondor, Assistance Publique-Hopitaux de Paris and UPEC, Creteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Henri Mondor, Assistance Publique-Hopitaux de Paris and UPEC, Creteil</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author><author><name sortKey="Cornely, Oliver A" sort="Cornely, Oliver A" uniqKey="Cornely O" first="Oliver A" last="Cornely">Oliver A. Cornely</name><affiliation wicri:level="1"><nlm:affiliation>Department I of Internal Medicine, Clinical Trials Centre Cologne, Centre for Integrated Oncology Köln Bonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, German Centre for Infection Research, University of Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department I of Internal Medicine, Clinical Trials Centre Cologne, Centre for Integrated Oncology Köln Bonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, German Centre for Infection Research, University of Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Pagliuca, Antonio" sort="Pagliuca, Antonio" uniqKey="Pagliuca A" first="Antonio" last="Pagliuca">Antonio Pagliuca</name><affiliation wicri:level="3"><nlm:affiliation>King's College Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>King's College Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Cragin, Lael" sort="Cragin, Lael" uniqKey="Cragin L" first="Lael" last="Cragin">Lael Cragin</name><affiliation wicri:level="2"><nlm:affiliation>Evidera, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Evidera, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Jarque, Isidro" sort="Jarque, Isidro" uniqKey="Jarque I" first="Isidro" last="Jarque">Isidro Jarque</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitari i Politècnic La Fe, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitari i Politècnic La Fe, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Garcia Vidal, Carolina" sort="Garcia Vidal, Carolina" uniqKey="Garcia Vidal C" first="Carolina" last="Garcia-Vidal">Carolina Garcia-Vidal</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Sorensen, Sonja" sort="Sorensen, Sonja" uniqKey="Sorensen S" first="Sonja" last="Sorensen">Sonja Sorensen</name><affiliation wicri:level="2"><nlm:affiliation>Evidera, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Evidera, Bethesda, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Vanness, David J" sort="Vanness, David J" uniqKey="Vanness D" first="David J" last="Vanness">David J. Vanness</name><affiliation wicri:level="2"><nlm:affiliation>University of Wisconsin and Visiting Scientist at Evidera, Madison, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Wisconsin and Visiting Scientist at Evidera, Madison, WI</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Charbonneau, Claudie" sort="Charbonneau, Claudie" uniqKey="Charbonneau C" first="Claudie" last="Charbonneau">Claudie Charbonneau</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer Inc, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer Inc, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Barrueta, Jon Andoni" sort="Barrueta, Jon Andoni" uniqKey="Barrueta J" first="Jon Andoni" last="Barrueta">Jon Andoni Barrueta</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer Inc, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pfizer Inc, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Peral, Carmen" sort="Peral, Carmen" uniqKey="Peral C" first="Carmen" last="Peral">Carmen Peral</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer Inc, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pfizer Inc, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="De Salas Cansado, Marina" sort="De Salas Cansado, Marina" uniqKey="De Salas Cansado M" first="Marina" last="De Salas-Cansado">Marina De Salas-Cansado</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer Inc, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Pfizer Inc, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Bow, Eric J" sort="Bow, Eric J" uniqKey="Bow E" first="Eric J" last="Bow">Eric J. Bow</name><affiliation wicri:level="4"><nlm:affiliation>CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>CancerCare Manitoba, University of Manitoba, Winnipeg, MB</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author></analytic><series><title level="j">Mycoses</title><idno type="eISSN">1439-0507</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antifungal Agents (economics)</term><term>Antifungal Agents (therapeutic use)</term><term>Cost-Benefit Analysis</term><term>Decision Support Techniques</term><term>Fluconazole (economics)</term><term>Fluconazole (therapeutic use)</term><term>Hematopoietic Stem Cell Transplantation</term><term>Humans</term><term>Invasive Fungal Infections (economics)</term><term>Invasive Fungal Infections (ethnology)</term><term>Invasive Fungal Infections (microbiology)</term><term>Invasive Fungal Infections (prevention & control)</term><term>Itraconazole (economics)</term><term>Itraconazole (therapeutic use)</term><term>Spain</term><term>Triazoles (economics)</term><term>Triazoles (therapeutic use)</term><term>Voriconazole (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Analyse coût-bénéfice</term><term>Antifongiques (usage thérapeutique)</term><term>Antifongiques (économie)</term><term>Espagne</term><term>Fluconazole (usage thérapeutique)</term><term>Fluconazole (économie)</term><term>Humains</term><term>Infections fongiques invasives ()</term><term>Infections fongiques invasives (ethnologie)</term><term>Infections fongiques invasives (microbiologie)</term><term>Infections fongiques invasives (économie)</term><term>Itraconazole (usage thérapeutique)</term><term>Itraconazole (économie)</term><term>Techniques d'aide à la décision</term><term>Transplantation de cellules souches hématopoïétiques</term><term>Triazoles (usage thérapeutique)</term><term>Triazoles (économie)</term><term>Voriconazole (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antifungal Agents</term><term>Fluconazole</term><term>Itraconazole</term><term>Triazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antifungal Agents</term><term>Fluconazole</term><term>Itraconazole</term><term>Triazoles</term><term>Voriconazole</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Invasive Fungal Infections</term></keywords><keywords scheme="MESH" qualifier="ethnologie" xml:lang="fr"><term>Infections fongiques invasives</term></keywords><keywords scheme="MESH" qualifier="ethnology" xml:lang="en"><term>Invasive Fungal Infections</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Infections fongiques invasives</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Invasive Fungal Infections</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Invasive Fungal Infections</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antifongiques</term><term>Fluconazole</term><term>Itraconazole</term><term>Triazoles</term><term>Voriconazole</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Antifongiques</term><term>Fluconazole</term><term>Infections fongiques invasives</term><term>Itraconazole</term><term>Triazoles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cost-Benefit Analysis</term><term>Decision Support Techniques</term><term>Hematopoietic Stem Cell Transplantation</term><term>Humans</term><term>Spain</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Analyse coût-bénéfice</term><term>Espagne</term><term>Humains</term><term>Infections fongiques invasives</term><term>Techniques d'aide à la décision</term><term>Transplantation de cellules souches hématopoïétiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients undergoing allogeneic haematopoietic stem cell transplantation (alloHSCT) are at risk of developing invasive fungal infections (IFIs). Even with introduction of oral triazole antifungal agents (fluconazole, itraconazole, posaconazole and voriconazole) IFI-associated morbidity and mortality rates and economic burden remain high. Despite their proven efficacy, it is currently unknown which is the most cost-effective antifungal prophylaxis (AFP) agent. To determine the costs and outcomes associated with AFP, a decision-analytic model was used to simulate treatment in a hypothetical cohort of 1000 patients undergoing alloHSCT from the perspective of the Spanish National Health System. Generic itraconazole was the least costly AFP (€162) relative to fluconazole (€500), posaconazole oral suspension (€8628) or voriconazole (€6850). Compared with posaconazole, voriconazole was associated with the lowest number of breakthrough IFIs (36 vs 60); thus, the model predicted fewer deaths from breakthrough IFI for voriconazole (24) than posaconazole (33), and the lowest predicted costs associated with other licensed antifungal treatment and IFI treatment in a cohort of 1000. Voriconazole resulted in cost savings of €4707 per patient compared with posaconazole. Itraconazole demonstrated a high probability of being cost-effective. As primary AFP in alloHSCT patients 180 days posttransplant, voriconazole was more likely to be cost-effective than posaconazole regarding cost per additional IFI and additional death avoided.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27562016</PMID><DateCreated><Year>2016</Year><Month>08</Month><Day>26</Day></DateCreated><DateCompleted><Year>2017</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2017</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0507</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Mycoses</Title><ISOAbbreviation>Mycoses</ISOAbbreviation></Journal><ArticleTitle>Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.</ArticleTitle><Pagination><MedlinePgn>79-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/myc.12552</ELocationID><Abstract><AbstractText>Patients undergoing allogeneic haematopoietic stem cell transplantation (alloHSCT) are at risk of developing invasive fungal infections (IFIs). Even with introduction of oral triazole antifungal agents (fluconazole, itraconazole, posaconazole and voriconazole) IFI-associated morbidity and mortality rates and economic burden remain high. Despite their proven efficacy, it is currently unknown which is the most cost-effective antifungal prophylaxis (AFP) agent. To determine the costs and outcomes associated with AFP, a decision-analytic model was used to simulate treatment in a hypothetical cohort of 1000 patients undergoing alloHSCT from the perspective of the Spanish National Health System. Generic itraconazole was the least costly AFP (€162) relative to fluconazole (€500), posaconazole oral suspension (€8628) or voriconazole (€6850). Compared with posaconazole, voriconazole was associated with the lowest number of breakthrough IFIs (36 vs 60); thus, the model predicted fewer deaths from breakthrough IFI for voriconazole (24) than posaconazole (33), and the lowest predicted costs associated with other licensed antifungal treatment and IFI treatment in a cohort of 1000. Voriconazole resulted in cost savings of €4707 per patient compared with posaconazole. Itraconazole demonstrated a high probability of being cost-effective. As primary AFP in alloHSCT patients 180 days posttransplant, voriconazole was more likely to be cost-effective than posaconazole regarding cost per additional IFI and additional death avoided.</AbstractText><CopyrightInformation>© 2016 The Authors. Mycoses Published by Blackwell Verlag GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Solano</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-3702-0817</Identifier><AffiliationInfo><Affiliation>Hospital Clínico, INCLIVA-University of Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slavin</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Royal Melbourne Hospital, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaul</LastName><ForeName>Alissa J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Evidera, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>David I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>University Hospitals Bristol NHS Foundation Trust, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordonnier</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hôpital Henri Mondor, Assistance Publique-Hopitaux de Paris and UPEC, Creteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornely</LastName><ForeName>Oliver A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department I of Internal Medicine, Clinical Trials Centre Cologne, Centre for Integrated Oncology Köln Bonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, German Centre for Infection Research, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagliuca</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cragin</LastName><ForeName>Lael</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Evidera, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarque</LastName><ForeName>Isidro</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hospital Universitari i Politècnic La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Vidal</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorensen</LastName><ForeName>Sonja</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Evidera, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanness</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>University of Wisconsin and Visiting Scientist at Evidera, Madison, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charbonneau</LastName><ForeName>Claudie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrueta</LastName><ForeName>Jon Andoni</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peral</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Salas-Cansado</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bow</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Studies</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Mycoses</MedlineTA><NlmUniqueID>8805008</NlmUniqueID><ISSNLinking>0933-7407</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014230">Triazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>304NUG5GF4</RegistryNumber><NameOfSubstance UI="D017964">Itraconazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>6TK1G07BHZ</RegistryNumber><NameOfSubstance UI="C101425">posaconazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>8VZV102JFY</RegistryNumber><NameOfSubstance UI="D015725">Fluconazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>JFU09I87TR</RegistryNumber><NameOfSubstance UI="D065819">Voriconazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003661" MajorTopicYN="N">Decision Support Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015725" MajorTopicYN="N">Fluconazole</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072742" MajorTopicYN="N">Invasive Fungal Infections</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017964" MajorTopicYN="N">Itraconazole</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065819" MajorTopicYN="N">Voriconazole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">antifungal prophylaxis</Keyword><Keyword MajorTopicYN="Y">azoles</Keyword><Keyword MajorTopicYN="Y">cost-effectiveness</Keyword><Keyword MajorTopicYN="Y">invasive fungal infections</Keyword><Keyword MajorTopicYN="Y">pharmacoeconomics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27562016</ArticleId><ArticleId IdType="doi">10.1111/myc.12552</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Catalogne</li><li>Communauté de Madrid</li><li>Grand Londres</li><li>Manitoba</li><li>Maryland</li><li>Wisconsin</li><li>Île-de-France</li></region><settlement><li>Barcelone</li><li>Créteil</li><li>Londres</li><li>Madrid</li><li>Paris</li><li>Winnipeg</li></settlement><orgName><li>Université du Manitoba</li></orgName></list><tree><country name="Espagne"><noRegion><name sortKey="Solano, Carlos" sort="Solano, Carlos" uniqKey="Solano C" first="Carlos" last="Solano">Carlos Solano</name></noRegion><name sortKey="Barrueta, Jon Andoni" sort="Barrueta, Jon Andoni" uniqKey="Barrueta J" first="Jon Andoni" last="Barrueta">Jon Andoni Barrueta</name><name sortKey="De Salas Cansado, Marina" sort="De Salas Cansado, Marina" uniqKey="De Salas Cansado M" first="Marina" last="De Salas-Cansado">Marina De Salas-Cansado</name><name sortKey="Garcia Vidal, Carolina" sort="Garcia Vidal, Carolina" uniqKey="Garcia Vidal C" first="Carolina" last="Garcia-Vidal">Carolina Garcia-Vidal</name><name sortKey="Jarque, Isidro" sort="Jarque, Isidro" uniqKey="Jarque I" first="Isidro" last="Jarque">Isidro Jarque</name><name sortKey="Peral, Carmen" sort="Peral, Carmen" uniqKey="Peral C" first="Carmen" last="Peral">Carmen Peral</name></country><country name="Australie"><noRegion><name sortKey="Slavin, Monica" sort="Slavin, Monica" uniqKey="Slavin M" first="Monica" last="Slavin">Monica Slavin</name></noRegion></country><country name="États-Unis"><region name="Maryland"><name sortKey="Shaul, Alissa J" sort="Shaul, Alissa J" uniqKey="Shaul A" first="Alissa J" last="Shaul">Alissa J. Shaul</name></region><name sortKey="Cragin, Lael" sort="Cragin, Lael" uniqKey="Cragin L" first="Lael" last="Cragin">Lael Cragin</name><name sortKey="Sorensen, Sonja" sort="Sorensen, Sonja" uniqKey="Sorensen S" first="Sonja" last="Sorensen">Sonja Sorensen</name><name sortKey="Vanness, David J" sort="Vanness, David J" uniqKey="Vanness D" first="David J" last="Vanness">David J. Vanness</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Marks, David I" sort="Marks, David I" uniqKey="Marks D" first="David I" last="Marks">David I. Marks</name></noRegion><name sortKey="Pagliuca, Antonio" sort="Pagliuca, Antonio" uniqKey="Pagliuca A" first="Antonio" last="Pagliuca">Antonio Pagliuca</name></country><country name="France"><region name="Île-de-France"><name sortKey="Cordonnier, Catherine" sort="Cordonnier, Catherine" uniqKey="Cordonnier C" first="Catherine" last="Cordonnier">Catherine Cordonnier</name></region><name sortKey="Charbonneau, Claudie" sort="Charbonneau, Claudie" uniqKey="Charbonneau C" first="Claudie" last="Charbonneau">Claudie Charbonneau</name></country><country name="Allemagne"><noRegion><name sortKey="Cornely, Oliver A" sort="Cornely, Oliver A" uniqKey="Cornely O" first="Oliver A" last="Cornely">Oliver A. Cornely</name></noRegion></country><country name="Canada"><region name="Manitoba"><name sortKey="Bow, Eric J" sort="Bow, Eric J" uniqKey="Bow E" first="Eric J" last="Bow">Eric J. Bow</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000D68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:27562016
|texte= Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:27562016" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |